$CYDY
CytoDyn Inc. Stock $cydy

$cydy Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000155837022014943 Filed on October 11, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2021 Q3
Revenue	$0.00	$0.00	$41.00K
YoY Change	-100.0%
Cost Of Revenue	$2.704M	$73.49M	$1.000K
YoY Change	270300.0%
Gross Profit	-$2.704M	-$73.49M	$40.00K
YoY Change	-6860.0%
Gross Profit Margin			97.56%
Selling, General & Admin	$6.333M	$10.34M	$7.617M
YoY Change	-16.86%	15.02%	-22.87%
% of Gross Profit			19042.5%
Research & Development	$576.0K	-$4.909M	$13.78M
YoY Change	-95.82%	-134.16%	-9.24%
% of Gross Profit			34460.0%
Depreciation & Amortization	$99.00K	$124.0K	$276.0K
YoY Change	-64.13%	-54.91%	-45.35%
% of Gross Profit			690.0%
Operating Expenses	$576.0K	$5.558M	$13.78M
YoY Change	-95.82%	-76.49%	-9.24%
Operating Profit	-$9.712M	-$79.05M	-$21.64M
YoY Change	-55.11%		-15.37%
Interest Expense	-$10.34M	-$2.216M	-$3.194M
YoY Change	223.7%	-12.24%	-39.21%
% of Operating Profit
Other Income/Expense, Net	-$940.0K	-$945.0K	-$35.00K
YoY Change	2585.71%		-137.23%
Pretax Income	-$20.99M	-$110.4M	-$45.34M
YoY Change	-53.7%	146.0%	47.05%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$20.99M	-$110.4M	-$45.34M
YoY Change	-53.7%	146.0%	47.05%
Net Earnings / Revenue			-110578.05%
Basic Earnings Per Share	-$0.03		-$0.07
Diluted Earnings Per Share	-$0.03	-$153.9K	-$0.07
COMMON SHARES
Basic Shares Outstanding	810.7M		660.2M
Diluted Shares Outstanding	787.9M		632.6M

Balance Sheet

Concept	2022 Q3	2022 Q2	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.676M	$4.231M	$6.533M
YoY Change	-28.42%	-87.53%	-64.1%
Cash & Equivalents	$4.676M	$4.231M	$6.533M
Short-Term Investments
Other Short-Term Assets	$5.181M	$6.284M	$4.654M
YoY Change	11.32%	191.06%	45.35%
Inventory	$17.93M	$17.93M	$91.56M
Prepaid Expenses	$4.143M	$5.198M	$3.381M
Receivables			$41.00K
Other Receivables			$0.00
Total Short-Term Assets	$9.857M	$10.52M	$102.8M
YoY Change	-90.41%	-70.87%	28.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$502.0K	$73.00K	$129.0K
YoY Change	289.15%	-45.52%	-75.52%
Goodwill
YoY Change
Intangibles		$132.0K	$1.390M
YoY Change		-92.01%
Long-Term Investments
YoY Change
Other Assets	$608.0K	$741.0K
YoY Change
Total Long-Term Assets	$18.54M	$18.67M	$2.184M
YoY Change	748.76%	-80.55%	-83.81%
TOTAL ASSETS
Total Short-Term Assets	$9.857M	$10.52M	$102.8M
Total Long-Term Assets	$18.54M	$18.67M	$2.184M
Total Assets	$28.39M	$29.19M	$105.0M
YoY Change	-72.95%	-77.9%	12.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$69.00M	$68.00M	$65.90M
YoY Change	4.7%	3.19%	208.65%
Accrued Expenses	$16.50M	$18.95M	$12.36M
YoY Change	33.41%	-20.73%	-66.53%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$36.83M	$36.24M	$51.33M
YoY Change	-28.25%	-42.24%	183.23%
Total Short-Term Liabilities	$122.3M	$123.2M	$129.6M
YoY Change	-5.65%	-19.26%	69.64%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$387.0K	$422.0K	$519.0K
YoY Change	-25.43%	-23.55%	65.29%
Total Long-Term Liabilities	$387.0K	$422.0K	$519.0K
YoY Change	-25.43%	-23.55%	-96.34%
TOTAL LIABILITIES
Total Short-Term Liabilities	$122.3M	$123.2M	$129.6M
Total Long-Term Liabilities	$387.0K	$422.0K	$519.0K
Total Liabilities	$122.7M	$123.6M	$130.2M
YoY Change	-5.73%	-19.28%	43.68%
SHAREHOLDERS EQUITY
Retained Earnings	-$782.9M	-$766.1M	-$599.4M
YoY Change	30.6%	38.37%
Common Stock	$813.0K	$720.0K	$644.0K
YoY Change	26.24%	15.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$94.31M	-$94.40M	-$25.19M
YoY Change
Total Liabilities & Shareholders Equity	$28.39M	$29.19M	$105.0M
YoY Change	-72.95%	-77.9%	12.43%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2021 Q3
OPERATING ACTIVITIES
Net Income	-$20.99M	-$110.4M	-$45.34M
YoY Change	-53.7%	146.0%	47.05%
Depreciation, Depletion And Amortization	$99.00K	$124.0K	$276.0K
YoY Change	-64.13%	-54.91%	-45.35%
Cash From Operating Activities	-$11.07M	-$6.044M	-$31.74M
YoY Change	-65.11%	-81.58%	-22.48%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$30.00K	$8.000K
YoY Change	-100.0%	-236.36%	-86.44%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$30.00K	-$8.000K
YoY Change	-100.0%	-236.36%	-86.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	11.52M	7.882M	4.348M
YoY Change	164.93%	-84.98%	-90.32%
NET CHANGE
Cash From Operating Activities	-11.07M	-6.044M	-31.74M
Cash From Investing Activities	0.000	30.00K	-8.000K
Cash From Financing Activities	11.52M	7.882M	4.348M
Net Change In Cash	445.0K	1.868M	-27.40M
YoY Change	-101.62%	-90.49%	-798.83%
FREE CASH FLOW
Cash From Operating Activities	-$11.07M	-$6.044M	-$31.74M
Capital Expenditures	$0.00	$30.00K	$8.000K
Free Cash Flow	-$11.07M	-$6.074M	-$31.75M
YoY Change	-65.12%	-81.47%	-22.58%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	787856000
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	632597000
CY2022Q3	dei	Entity Central Index Key EntityCentralIndexKey	0001175680
CY2022Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--05-31
CY2022Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q3	dei	Amendment Flag AmendmentFlag	false
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	787856000
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	632597000
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2022Q3	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.cytodyn.com/20220831#AccruedCompensationAndNonFinancingLiabilities
CY2022Q2	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.cytodyn.com/20220831#AccruedCompensationAndNonFinancingLiabilities
CY2022Q3	dei	No Trading Symbol Flag NoTradingSymbolFlag	true
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2022Q2	us-gaap	Derivative Liabilities DerivativeLiabilities
CY2022Q3	us-gaap	Derivative Liabilities DerivativeLiabilities
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2022Q3	dei	Amendment Flag AmendmentFlag	false
CY2022Q3	dei	Document Type DocumentType	10-Q
CY2022Q3	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q3	dei	Document Period End Date DocumentPeriodEndDate	2022-08-31
CY2022Q3	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q3	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity File Number EntityFileNumber	000-49908
CY2022Q3	dei	Entity Registrant Name EntityRegistrantName	CYTODYN INC.
CY2022Q3	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q3	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-1887078
CY2022Q3	dei	Entity Address Address Line1 EntityAddressAddressLine1	1111 Main Street
CY2022Q3	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 660
CY2022Q3	dei	Entity Address City Or Town EntityAddressCityOrTown	Vancouver
CY2022Q3	dei	Entity Address State Or Province EntityAddressStateOrProvince	WA
CY2022Q3	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	98660
CY2022Q3	dei	City Area Code CityAreaCode	360
CY2022Q3	dei	Local Phone Number LocalPhoneNumber	980-8524
CY2022Q3	dei	Security12b Title Security12bTitle	None
CY2022Q3	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q3	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q3	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q3	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q3	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	812825217
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4676000
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4231000
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4143000
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5198000
CY2022Q3	cydy	Prepaid Service Fees Current PrepaidServiceFeesCurrent	1038000
CY2022Q2	cydy	Prepaid Service Fees Current PrepaidServiceFeesCurrent	1086000
CY2022Q3	us-gaap	Assets Current AssetsCurrent	9857000
CY2022Q2	us-gaap	Assets Current AssetsCurrent	10515000
CY2022Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	17929000
CY2022Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	17929000
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	608000
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	741000
CY2022Q3	us-gaap	Assets Assets	28394000
CY2022Q2	us-gaap	Assets Assets	29185000
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	68991000
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	67974000
CY2022Q3	cydy	Accrued Compensation And Non Financing Liabilities AccruedCompensationAndNonFinancingLiabilities	5014000
CY2022Q2	cydy	Accrued Compensation And Non Financing Liabilities AccruedCompensationAndNonFinancingLiabilities	8995000
CY2022Q3	us-gaap	Interest Payable Current InterestPayableCurrent	7120000
CY2022Q2	us-gaap	Interest Payable Current InterestPayableCurrent	5974000
CY2022Q3	us-gaap	Dividends Payable Current DividendsPayableCurrent	4361000
CY2022Q2	us-gaap	Dividends Payable Current DividendsPayableCurrent	3977000
CY2022Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	36833000
CY2022Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	36241000
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	122319000
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	123161000
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	387000
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	422000
CY2022Q3	us-gaap	Liabilities Liabilities	122706000
CY2022Q2	us-gaap	Liabilities Liabilities	123583000
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1350000000
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1350000000
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	812698000
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	720028000
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	812255000
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	719585000
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	813000
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	720000
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	443000
CY2022Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	443000
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	687732000
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	671013000
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-782857000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-766131000
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-94312000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-94398000
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	28394000
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	29185000
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	41000
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	1000
CY2021Q3	us-gaap	Gross Profit GrossProfit	40000
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6333000
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7617000
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	576000
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12020000
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	99000
CY2021Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	276000
CY2022Q3	us-gaap	Inventory Write Down InventoryWriteDown	2704000
CY2021Q3	us-gaap	Inventory Write Down InventoryWriteDown	1764000
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	9712000
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	21677000
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9712000
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-21637000
CY2022Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	1146000
CY2021Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	1686000
CY2022Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	576000
CY2021Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	952000
CY2022Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	16000
CY2021Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	28000
CY2021Q3	cydy	Loss On Induced Conversion Of Debt LossOnInducedConversionOfDebt	18530000
CY2022Q3	cydy	Finance Charge Adjustments FinanceChargeAdjustments	940000
CY2021Q3	cydy	Finance Charge Adjustments FinanceChargeAdjustments	35000
CY2021Q3	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	528000
CY2021Q3	cydy	Non Operating Legal Settlement Expense NonOperatingLegalSettlementExpense	-1941000
CY2022Q3	cydy	Gain Loss On Derivatives GainLossOnDerivatives	-8601000
CY2022Q3	us-gaap	Interest And Debt Expense InterestAndDebtExpense	11279000
CY2021Q3	us-gaap	Interest And Debt Expense InterestAndDebtExpense	23700000
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20991000
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-45337000
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-20991000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-45337000
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	787856000
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	632597000
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-94398000
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	345000
CY2022Q3	cydy	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Excluding Legal Fees AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsExcludingLegalFees	6289000
CY2022Q3	cydy	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	264000
CY2022Q3	cydy	Adjustment To Additional Paid In Capital Accrued Preferred Stock Dividends AdjustmentToAdditionalPaidInCapitalAccruedPreferredStockDividends	384000
CY2022Q3	cydy	Adjustments To Additional Paid In Capital Warrant Issuance Cost AdjustmentsToAdditionalPaidInCapitalWarrantIssuanceCost	8601000
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	996000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-20991000
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-94312000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-21018000
CY2021Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	13844000
CY2021Q3	cydy	Loss On Induced Conversion Of Debt LossOnInducedConversionOfDebt	18530000
CY2021Q3	cydy	Issuance Of Stock Value Legal Settlement IssuanceOfStockValueLegalSettlement	1744000
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	189000
CY2021Q3	cydy	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	503000
CY2021Q3	cydy	Inducement Interest Expense Related To Private Warrant Exchange InducementInterestExpenseRelatedToPrivateWarrantExchange	528000
CY2021Q3	cydy	Adjustment To Additional Paid In Capital Accrued Preferred Stock Dividends AdjustmentToAdditionalPaidInCapitalAccruedPreferredStockDividends	420000
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2597000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-45337000
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-25193000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-20991000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-45337000
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	99000
CY2021Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	276000
CY2022Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	16000
CY2021Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	28000
CY2022Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	576000
CY2021Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	952000
CY2021Q3	cydy	Adjustment To Reconcile Net Loss To Net Cash Used In Operating Activities Litigation Settlement AdjustmentToReconcileNetLossToNetCashUsedInOperatingActivitiesLitigationSettlement	1744000
CY2022Q3	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-8601000
CY2021Q3	cydy	Loss On Induced Conversion Of Debt LossOnInducedConversionOfDebt	18530000
CY2021Q3	cydy	Inducement Interest Expense And Non Cash Finance Charges InducementInterestExpenseAndNonCashFinanceCharges	528000
CY2022Q3	us-gaap	Inventory Write Down InventoryWriteDown	2704000
CY2021Q3	us-gaap	Inventory Write Down InventoryWriteDown	1764000
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1341000
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	2597000
CY2022Q3	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1601000
CY2021Q3	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2370000
CY2022Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1819000
CY2021Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-10453000
CY2022Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11074000
CY2021Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-31741000
CY2021Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8000
CY2021Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8000
CY2021Q3	cydy	Proceeds From Warrant Transactions Net ProceedsFromWarrantTransactionsNet	775000
CY2022Q3	cydy	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	11255000
CY2021Q3	cydy	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	2872000
CY2022Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	264000
CY2021Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	503000
CY2021Q3	cydy	Increase Decrease In Exercise Of Option To Repurchase Shares Held In Escrow IncreaseDecreaseInExerciseOfOptionToRepurchaseSharesHeldInEscrow	9000
CY2021Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	189000
CY2022Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11519000
CY2021Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4348000
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	445000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-27401000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4231000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33943000
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4676000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6542000
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4676000
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6533000
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	9000
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4676000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6542000
CY2021Q3	us-gaap	Interest Paid Net InterestPaidNet	35000
CY2021Q3	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	14950000
CY2022Q3	cydy	Dividends On Convertible Preferred Stock Incurred But Not Yet Paid. DividendsOnConvertiblePreferredStockIncurredButNotYetPaid.	384000
CY2021Q3	cydy	Dividends On Convertible Preferred Stock Incurred But Not Yet Paid. DividendsOnConvertiblePreferredStockIncurredButNotYetPaid.	420000
CY2022Q3	cydy	Common Stock Issued Due To Round Down Provision CommonStockIssuedDueToRoundDownProvision	4154000
CY2022Q3	cydy	Inventory With Shelf Life Less Than One Year InventoryWithShelfLifeLessThanOneYear	6903000
CY2022Q3	cydy	Inventory With Shelf Life From One To Two Years InventoryWithShelfLifeFromOneToTwoYears	20201000
CY2022Q3	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Reclassifications</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain prior year and prior quarter amounts shown in the accompanying consolidated financial statements have been reclassified to conform to the current period presentation. Such reclassifications did not have material effect on the Company’s previously reported financial position, results of operations, stockholders’ deficit, or net cash provided by operating activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the quarter ended August 31, 2022, the Company reclassified amounts recorded as accumulated dividends for Series C and D preferred stockholders from accumulated deficit to additional paid-in capital. These reclassifications were made to reflect the proper presentation for accrued dividends when an entity has accumulated deficit. </p>
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-21000000.0
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-782900000
CY2022Q3	cydy	Inventory Work In Progress Noncurrent InventoryWorkInProgressNoncurrent	1665000
CY2022Q2	cydy	Inventory Work In Progress Noncurrent InventoryWorkInProgressNoncurrent	1665000
CY2022Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	17929000
CY2022Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	17929000
CY2022Q3	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States (U.S. GAAP) requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Estimates are assessed each period and updated to reflect current information, such as the status of our analysis of the results of our clinical trials and/or discussions with the FDA which could have an impact on the Company’s significant accounting estimates and assumptions. The Company’s estimates are based on historical experience and on various market and other relevant, appropriate assumptions. Significant estimates include, but are not limited to, those relating to stock-based compensation, capitalization of pre-launch inventories, write-off for excess and obsolete inventories, research and development expenses, commitments and contingencies, and the assumptions used to value warrants and warrant modifications. Actual results could differ from these estimates. </p>
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	4200000
CY2022Q3	cydy	Inventory Raw Material Noncurrent InventoryRawMaterialNoncurrent	16264000
CY2022Q2	cydy	Inventory Raw Material Noncurrent InventoryRawMaterialNoncurrent	16264000
CY2022Q3	cydy	Inventory With Shelf Life From Two To Three Years InventoryWithShelfLifeFromTwoToThreeYears	31241000
CY2022Q3	cydy	Inventory With Shelf Life From Three To Four Years InventoryWithShelfLifeFromThreeToFourYears	35779000
CY2022Q3	cydy	Inventory Gross Noncurrent InventoryGrossNoncurrent	94124000
CY2022Q3	cydy	Inventory Write Off Noncurrent InventoryWriteOffNoncurrent	76195000
CY2022Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	17929000
CY2022Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	10200000
CY2022Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	10200000
CY2022	cydy	Inventory Number Of Batches Not Saleable InventoryNumberOfBatchesNotSaleable	5
CY2022	cydy	Total Number Of Batches Not Saleable TotalNumberOfBatchesNotSaleable	9
CY2022Q3	cydy	Share Based Compensation Number Of Inactive Plans ShareBasedCompensationNumberOfInactivePlans	1
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	69000000.0
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	68000000.0
CY2022Q3	cydy	Number Of Counterparties NumberOfCounterparties	2
CY2022Q2	cydy	Number Of Counterparties NumberOfCounterparties	2
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	792000
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1522000
CY2022Q3	us-gaap	Litigation Reserve Current LitigationReserveCurrent	1017000
CY2022Q2	us-gaap	Litigation Reserve Current LitigationReserveCurrent	2006000
CY2022Q3	cydy	Accrued Clinical Expenses AccruedClinicalExpenses	311000
CY2022Q2	cydy	Accrued Clinical Expenses AccruedClinicalExpenses	3727000
CY2022Q3	cydy	Unbilled Inventory UnbilledInventory	2218000
CY2022Q2	cydy	Unbilled Inventory UnbilledInventory	1392000
CY2022Q3	cydy	Accrued License Fees Current AccruedLicenseFeesCurrent	541000
CY2022Q2	cydy	Accrued License Fees Current AccruedLicenseFeesCurrent	150000
CY2022Q3	cydy	Accrued Lease Payable AccruedLeasePayable	135000
CY2022Q2	cydy	Accrued Lease Payable AccruedLeasePayable	134000
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	64000
CY2022Q3	cydy	Accrued Compensation And Non Financing Liabilities AccruedCompensationAndNonFinancingLiabilities	5014000
CY2022Q2	cydy	Accrued Compensation And Non Financing Liabilities AccruedCompensationAndNonFinancingLiabilities	8995000
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	46000.0
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	48900
CY2022Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	38319000
CY2021Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	38319000
CY2022Q3	us-gaap	Deferred Finance Costs Noncurrent Gross DeferredFinanceCostsNoncurrentGross	1486000
CY2021Q2	us-gaap	Deferred Finance Costs Noncurrent Gross DeferredFinanceCostsNoncurrentGross	2078000
CY2022Q3	cydy	Long Term Debt Including Accrued Interest LongTermDebtIncludingAccruedInterest	36833000
CY2021Q2	cydy	Long Term Debt Including Accrued Interest LongTermDebtIncludingAccruedInterest	36241000
CY2022Q3	cydy	Accrued Interest Noncurrent AccruedInterestNoncurrent	7120000
CY2021Q2	cydy	Accrued Interest Noncurrent AccruedInterestNoncurrent	5974000
CY2022Q3	us-gaap	Long Term Debt LongTermDebt	43953000
CY2021Q2	us-gaap	Long Term Debt LongTermDebt	42215000
CY2022Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	42215000
CY2022Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	592000
CY2022Q3	cydy	Interest Expense Accrued InterestExpenseAccrued	1146000
CY2022Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	43953000
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000.0
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1350000000
CY2022Q3	cydy	Warrant Becoming Liability WarrantBecomingLiability	14522000
CY2022Q3	cydy	Warrant Equity Classified WarrantEquityClassified	23123000
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	8601000
CY2022Q3	cydy	Share Based Compensation Number Of Active Plans ShareBasedCompensationNumberOfActivePlans	1
CY2022Q2	cydy	Stock Options And Warrants Outstanding Numbers StockOptionsAndWarrantsOutstandingNumbers	90705
CY2022Q2	cydy	Stock Options And Warrants Outstanding Weighted Average Exercise Price StockOptionsAndWarrantsOutstandingWeightedAverageExercisePrice	0.77
CY2022	cydy	Stock Options And Warrants Outstanding Weighted Average Remaining Contractual Life Term StockOptionsAndWarrantsOutstandingWeightedAverageRemainingContractualLifeTerm	P4Y21D
CY2022Q2	cydy	Stock Options And Warrants Outstanding Aggregate Intrinsic Value StockOptionsAndWarrantsOutstandingAggregateIntrinsicValue	352000
CY2022Q3	cydy	Stock Options And Warrants Grants In Period StockOptionsAndWarrantsGrantsInPeriod	104104
CY2022Q3	cydy	Stock Options And Warrants Grants In Period Weighted Average Exercise Price StockOptionsAndWarrantsGrantsInPeriodWeightedAverageExercisePrice	0.25
CY2022Q3	cydy	Stock Options And Warrants Exercised In Period StockOptionsAndWarrantsExercisedInPeriod	863
CY2022Q3	cydy	Stock Options And Warrants Exercised In Period Weighted Average Exercise Price StockOptionsAndWarrantsExercisedInPeriodWeightedAverageExercisePrice	0.49
CY2022Q3	cydy	Stock Options And Warrants Forfeitures And Expirations In Period StockOptionsAndWarrantsForfeituresAndExpirationsInPeriod	484
CY2022Q3	cydy	Stock Options And Warrants Forfeitures And Expirations In Period Weighted Average Exercise Price StockOptionsAndWarrantsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	1.57
CY2022Q3	cydy	Stock Options And Warrants Outstanding Numbers StockOptionsAndWarrantsOutstandingNumbers	193462
CY2022Q3	cydy	Stock Options And Warrants Outstanding Weighted Average Exercise Price StockOptionsAndWarrantsOutstandingWeightedAverageExercisePrice	0.48
CY2022Q3	cydy	Stock Options And Warrants Outstanding Weighted Average Remaining Contractual Life Term StockOptionsAndWarrantsOutstandingWeightedAverageRemainingContractualLifeTerm	P4Y4M9D
CY2022Q3	cydy	Stock Options And Warrants Outstanding Aggregate Intrinsic Value StockOptionsAndWarrantsOutstandingAggregateIntrinsicValue	36758000
CY2022Q3	cydy	Stock Options And Warrants Outstanding Exercisable Number StockOptionsAndWarrantsOutstandingExercisableNumber	187896
CY2022Q3	cydy	Stock Options And Warrants Outstanding Exercisable Weighted Average Exercise Price StockOptionsAndWarrantsOutstandingExercisableWeightedAverageExercisePrice	0.45
CY2022Q3	cydy	Stock Options And Warrants Outstanding Exercisable Weighted Average Remaining Contractual Term StockOptionsAndWarrantsOutstandingExercisableWeightedAverageRemainingContractualTerm	P4Y2M26D
CY2022Q3	cydy	Stock Options And Warrants Outstanding Exercisable Aggregate Intrinsic Value StockOptionsAndWarrantsOutstandingExercisableAggregateIntrinsicValue	36717000
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	11900000
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	5300000
CY2022Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2800000
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.40
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.255
CY2022Q3	cydy	Class Of Warrant Covering Common Stock Shares Purchased Percentage ClassOfWarrantCoveringCommonStockSharesPurchasedPercentage	0.50
CY2022Q3	cydy	Class Of Warrant Covering Common Stock Shares Purchased Percentage ClassOfWarrantCoveringCommonStockSharesPurchasedPercentage	0.75
CY2022Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	4600000
CY2022Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	5500000
CY2022Q3	cydy	Warrant Down Round Feature Increase Decrease In Equity Amount1 WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1	4200000
CY2022Q3	cydy	Stock Issued During Period Shares Warrants Exercised StockIssuedDuringPeriodSharesWarrantsExercised	500000
CY2022Q3	cydy	Stock Issued During Period Value Warrants Exercised Cash StockIssuedDuringPeriodValueWarrantsExercisedCash	300000
CY2022Q3	cydy	Stock Issued During Period Non Cash Shares Warrant Exercised StockIssuedDuringPeriodNonCashSharesWarrantExercised	200000
CY2022Q3	cydy	Warrants Exercised Noncash Number Of Warrants WarrantsExercisedNoncashNumberOfWarrants	300000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-20991000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-45337000
CY2022Q3	cydy	Deemed Dividend Down Round Feature Decrease In Net Income To Common Shareholder Amount DeemedDividendDownRoundFeatureDecreaseInNetIncomeToCommonShareholderAmount	4154000
CY2022Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	385000
CY2021Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	425000
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25530000
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-45762000
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	787856000
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	632597000
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022Q3	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	502000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	536000
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	135000
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	134000
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	387000
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	422000
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	522000
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	556000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	133000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	182000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	185000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	169000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	669000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	147000
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	522000
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y7M6D
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.100

Files In Submission

Name	View Source	Status
0001558370-22-014943-index-headers.html	Edgar Link	pending
0001558370-22-014943-index.html	Edgar Link	pending
0001558370-22-014943.txt	Edgar Link	pending
0001558370-22-014943-xbrl.zip	Edgar Link	pending
cydy-20220831.xsd	Edgar Link	pending
cydy-20220831x10q.htm	Edgar Link	pending
cydy-20220831xex31d1.htm	Edgar Link	pending
cydy-20220831xex31d2.htm	Edgar Link	pending
cydy-20220831xex32.htm	Edgar Link	pending
cydy-20220831xex3d1.htm	Edgar Link	pending
cydy-20220831xex3d1001.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
cydy-20220831_cal.xml	Edgar Link	unprocessable
cydy-20220831_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cydy-20220831_lab.xml	Edgar Link	unprocessable
cydy-20220831_pre.xml	Edgar Link	unprocessable
cydy-20220831x10q_htm.xml	Edgar Link	completed
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CYDY
CytoDyn Inc. Stock $cydy

2022 Q3 Form 10-Q Financial Statement

#000155837022014943 Filed on October 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYDY CytoDyn Inc. Stock $cydy

2022 Q3 Form 10-Q Financial Statement

#000155837022014943 Filed on October 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYDY
CytoDyn Inc. Stock $cydy